Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | IDH2 |
Variant | R140W |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | IDH2 R140W lies within the substrate binding region of the Idh2 protein (UniProt.org). R140W results in decreased conversion of isocitrate to alpha-ketoglutarate (alpha-KG) by Idh2, and also results in increased conversion of alpha-KG to 2HG (R(-)-2-hydroxyglutarate) in an in vitro assay (PMID: 21647154), and therefore, is predicted to lead to a gain of Idh2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
IDH2 mutant IDH2 act mut IDH2 R140W IDH2 mutant IDH2 R140X IDH2 R140W |
Transcript | NM_002168.4 |
gDNA | chr15:g.90088703G>A |
cDNA | c.418C>T |
Protein | p.R140W |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002168.3 | chr15:g.90088703G>A | c.418C>T | p.R140W | RefSeq | GRCh38/hg38 |
NM_002168 | chr15:g.90088703G>A | c.418C>T | p.R140W | RefSeq | GRCh38/hg38 |
NM_002168.4 | chr15:g.90088703G>A | c.418C>T | p.R140W | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Active, not recruiting | USA | 0 |